Can a Navigator and $2,000 in Reimbursements Close the Cancer Clinical Trial Gap? A New Randomized Trial Puts GUIDE to the Test

For decades, the promise of cancer clinical trials has been shadowed by a stubborn paradox: the patients who stand to gain the most from experimental therapies are often the least likely to enroll in the studies that test them. Socioeconomically disadvantaged populations remain persistently underrepresented in oncology trials, and the consequences ripple far beyond individual patients. When trial participants do not reflect the diversity of the population that will eventually receive the treatments, the generalizability of trial results suffers, and existing health disparities widen. A research team at Fred Hutchinson Cancer Center in Seattle believes it has identified a practical, testable remedy, and it has now published the full protocol of a randomized controlled trial designed to prove whether that remedy works.

The intervention is called GUIDE, short for Guiding participation toward Understanding, Inclusion, Diversity, and Equity in Cancer Clinical Trials. Described in a methods article published in Frontiers in Cancer Control and Society, GUIDE is a multilevel clinical trial navigation program that pairs two components rarely combined in a single intervention: dedicated navigation services delivered by a trained clinical trial navigator, and financial reimbursement of up to $2,000 for trial-related expenses. The program was developed using established behavioral intervention guidelines, specifically the ORBIT phase 1A framework, and its design was informed by qualitative interviews with patients and providers about the barriers they perceive in trial participation.

The trial itself is a pilot randomized controlled study of 100 adults with cancer who are eligible for a therapeutic clinical trial. Participants are randomized one-to-one to receive GUIDE alongside usual care, or usual care alone, for a six-month period. Usual care at the study site, an National Cancer Institute-designated comprehensive cancer center, is already substantial: patients have access to social work, patient and financial navigation, a patient and family resource center, housing options, nutrition services, and spiritual health teams. The comparison is therefore a rigorous one, testing whether GUIDE adds measurable value on top of a well-resourced standard of care.

Eligibility for the study hinges on health-related social needs, the nonmedical conditions such as housing, transportation, and food insecurity that shape health outcomes. Participants qualify if they report transportation, food, or housing insecurity or financial hardship on an institutional questionnaire; if they or their providers express concern about trial participation due to such needs; if they have Medicaid insurance; or if they request assistance with social needs. Recruitment flows through two channels: oncologist referral and a pre-existing clinical trial prescreening program in which clinical research nurses systematically identify patients who meet eligibility criteria for open trials across five clinics, covering breast, genitourinary, lymphoma, myeloma, and head and neck cancers.

Once enrolled, participants in the intervention arm are assigned a Guide, a staff member holding a master’s degree in health administration and certifications from the American Cancer Society in oncology navigation, clinical trial navigation, and navigation leadership. The Guide’s role is deliberately broad. In an initial meeting, the Guide introduces the therapeutic trial under consideration or reviews the schedule of required visits and assessments if the patient has already consented. The Guide then assesses for household material hardship, insurance status, and other participation barriers, and connects patients to institutional resources such as the cancer center’s Patient and Family Assistance fund, as well as community resources including 211 information services and disease-specific support organizations. The Guide meets with participants at least monthly by phone, video, or in person for six months, regardless of whether the patient ultimately enrolls in a trial.

The financial component is the program’s most distinctive feature. Participants can receive up to $2,000 in reimbursement for trial-related expenses, with a predefined list of qualifying costs that includes temporary housing, mileage, taxi and rideshare fares, public transportation, parking, laundry, hotel Wi-Fi, childcare, eldercare, and meals for patients and caregivers attending trial appointments. Luxury upgrades, personal travel extensions, guest meals, alcohol, and entertainment are explicitly excluded. Patients receive monthly updates on remaining funds, and even those who incur expenses while determining their trial eligibility can be reimbursed. If a patient is found ineligible for the therapeutic trial or discontinues participation, reimbursement ends but navigation services continue.

The trial’s primary outcomes focus on implementation science rather than efficacy alone. The researchers will evaluate GUIDE’s feasibility, acceptability, and appropriateness using Proctor’s implementation outcomes framework, assessed at six months through patient and provider interviews and survey data. Exploratory outcomes are broader: clinical trial enrollment and retention, patient trust measured with the Interpersonal Physician Trust Scale, health-related quality of life via the PROMIS Global Health Score, resilience using the Connor-Davidson Resilience Scale, health-related social needs assessed with the Health Leads Screening Toolkit, and financial burden quantified by the Functional Assessment of Chronic Illness Therapy Comprehensive Score for Financial Toxicity. A subset of 20 intervention participants, including all who identify as members of historically marginalized racial or ethnic groups, will complete semistructured qualitative interviews exploring their experiences with both the navigator and the reimbursement process.

The statistical approach reflects the pilot nature of the study. With 50 participants per arm and an anticipated 90 percent retention rate, the trial has at least 80 percent power to detect a 0.56 standard deviation difference in continuous outcomes, with 95 percent confidence interval half-widths of approximately 0.4 standard deviations. The researchers explicitly state that no formal hypothesis testing will be performed on preliminary efficacy outcomes; instead, they will report point estimates and confidence intervals to inform the design of fully powered future trials. Analyses will use an intent-to-treat approach, and the team will examine outcomes separately in low- and high-income subgroups to determine whether the reimbursement model’s effectiveness differs by socioeconomic status, an important consideration given that the model requires participants to pay upfront and seek reimbursement later.

That upfront-payment structure is one of the program’s acknowledged limitations. The researchers note that some patients are not positioned to benefit from a reimbursement model at all, because it requires covering trial-related expenses with their own funds before being paid back, which is not feasible for the most financially disadvantaged. The team explored alternative modes of financial support, including direct cash transfers, debit cards, and gift cards, but was unable to overcome bureaucratic barriers, including concerns about undue inducement, to implement them. The researchers also acknowledge that randomization occurs only after trial eligibility is fully determined, meaning upstream factors such as permissive eligibility criteria and trial decentralization, which may safeguard against the systematic exclusion of marginalized populations, fall outside GUIDE’s reach.

Enrollment for the pilot trial began on July 15, 2024, and was completed by July 14, 2025, with data collection concluding in January 2026. The study is registered at ClinicalTrials.gov under identifier NCT06484595 and was funded by the Andy Hill Cancer Research Endowment Fund. Whether GUIDE demonstrates meaningful improvements in trial enrollment and retention remains to be seen, but the publication of its full protocol addresses a gap the researchers identify as critical: clinical trial navigation programs are highly heterogeneous, and the components of effective programs remain poorly understood, in part because few protocols have been published. By laying out its methods in detail, the GUIDE team aims to give the field a transparent template for what a multilevel trial navigation program actually looks like in practice, and a benchmark against which future interventions can be measured.

Subject of Research: A pilot randomized controlled trial evaluating a clinical trial navigation and reimbursement program to reduce disparities in cancer clinical trial access

Article Title: Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

Article References: Karvonen, K. A., McDougall, J. A., Carosso, E. A., Burrows, T., Mecham, S. H., Di, C., Hohl, S. D., Stohr, E., Devine, A., Linden, H., Gopal, A. K., Yu, E. Y., Cowan, A. J., & Mendoza, J. A. (2026). Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement. Frontiers in Cancer Control and Society, 4, Article 1794900. https://doi.org/10.3389/fcacs.2026.1794900

Image Credits: AI Generated

DOI: 10.3389/fcacs.2026.1794900

Keywords: clinical trials, cancer, patient navigation, health equity, financial reimbursement, social determinants of health, randomized controlled trial, Fred Hutchinson Cancer Center, health-related social needs, implementation science, financial toxicity, oncology